I read old LRB/NYRB issues a year or two late. This 2023 Jerome Groopman piece is grim: cancer treatment as lucrative market, with investors drawn to drugs that “don’t work too well” or cure too quickly—so the patient/customer keeps paying. Photos attached; paywalled link in comments.
